Michael Guarnieri

Dr. Michael Guarnieri


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MIMariaLisa Itzoe
MariaLisa Itzoe
MGMichael Guarnieri
Michael Guarnieri
Opioid addiction to prescription and illicit drugs is a serious and growing problem. In the US alone, >2.4 million people suffer from opioid use disorder. Government and pharmaceutical agencies have begun to address this crisis with recently released and revised task forces and medication-assisted therapies (MAT). For decades, oral or intravenous (IV) MATs have helped patients in their recovery by administration of opioid agonists (methadone, buprenorphine, oxycodone), antagonists (naltrexone, naloxone), and combinations of the two (buprenorphine/naloxone). While shown to be successful, particularly when combined with psychological counseling, oral and IV forms of treatment come with constraints and challenges. Patients can become addicted to the agonists themselves, and there is increased risk for diversion, abuse, or missed dosages. Consequently, long-acting implants have begun to be developed as a potentially preferable method of agonist delivery. To date, the newest implant approved by the US Food and Drug Administration (May 2016) is Probuphine®, which delivers steady-state levels of buprenorphine over the course of 6 months. Numerous studies have demonstrated its efficacy and safety. Yet, implants come with their own risks such as surgical site irritation, possible movement, and protrusion of implant out of skin. This review introduces the opioid abuse epidemic, examines existing medications used for therapy, and highlights Probuphine as a new treatment option. Costs associated with MATs are also discussed.

14 October 2004 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
NHNicola C. Ho
Nicola C. Ho
MGMichael Guarnieri
Michael Guarnieri
LBLarry J. Brant
Larry J. Brant
SPSusan S. Park
Susan S. Park
BSBonnie Sun
Bonnie Sun
BCBenjamin S. Carson
Benjamin S. Carson

1 January 2014 in Journal of Pharmacy and Bioallied Sciences
Verified
Journal Article
Open access
PDF file
MGMichael Guarnieri
Michael Guarnieri
BTBetty M Tyler
Betty M Tyler
LDLouis DeTolla
Louis DeTolla
MZMing Zhao
Ming Zhao
BKBarry Kobrin
Barry Kobrin
Background: Long-acting therapy in laboratory animals offers advantages over the current practice of 2-3 daily drug injections. Yet little is known about the disintegration of biodegradable drug implants in rodents. Objective: Compare bioavailability of buprenorphine with the biodegradation of lipid-encapsulated subcutaneous drug pellets. Methods: Pharmacokinetic and histopathology studies were conducted in BALB/c female mice implanted with cholesterol-buprenorphine drug pellets. Results: Drug levels are below the level of detection (0.5 ng/mL plasma) within 4-5 days of implant. However, necroscopy revealed that interstitial tissues begin to seal implants within a week. Visual inspection of the implant site revealed no evidence of inflammation or edema associated with the cholesterol-drug residue. Chemical analyses demonstrated that the residues contained 10-13% of the initial opiate dose for at least two weeks post implant. Discussion: The results demonstrate that biodegradable scaffolds can become sequestered in the subcutaneous space. Conclusion: Drug implants can retain significant and unintended reservoirs of drugs.

1 June 2005 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
MGMichael Guarnieri
Michael Guarnieri
BCBenjamin S. Carson
Benjamin S. Carson
Andleeb KhanAndleeb Khan
Andleeb Khan
MPMargaret Penno
Margaret Penno
GJGeorge I. Jallo
George I. Jallo

1 January 2014 in Journal of Pharmacy and Bioallied Sciences
Verified
Journal Article
Open access
PDF file
MGMichael Guarnieri
Michael Guarnieri
NSNoam Schildhaus
Noam Schildhaus
ETEliana Trink
Eliana Trink
CPChirs Polson
Chirs Polson
LDLouis DeTolla
Louis DeTolla
STSino Tok
Sino Tok
Background: The change in the reaction time of a tail or paw exposed to a thermal stimulus is a measure of nociceptive activity in laboratory animals. Tail-flick and plantar thermal sensitivity (Hargreaves) tests are non-invasive, minimize stress, and can be used to screen animals for phenotype and drug activity. Objective: Hargreaves testing has been widely used in rats. We investigated its use to measure the activity of opiate analgesia in mice. Methods: Mice were used in thermal stimulus studies at 1-5 hours and 1-5 days to test acute and extended release preparations of buprenorphine. Results: Hargreaves testing had limited value at 1-5 hours because mice can have an obtunded response to opiate therapy. Tail-flick studies with restrained mice are not affected by the initial locomotor stimulation. Discussion: The present report describes a simple restraint system for mice. The utility of the system is demonstrated by examining the efficacy of acute and extended release buprenorphine injections in Balb/c and Swiss mice. Conclusion: Standardized tail-flick testing provides a sensitive robust method to monitor opiate activity in mice.

15 August 2006 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
JLJames Lee
James Lee
GJGeorge I. Jallo
George I. Jallo
MPMargaret B. Penno
Margaret B. Penno
KGKathleen L. Gabrielson
Kathleen L. Gabrielson
GYG. David Young
G. David Young
MGMichael Guarnieri
Michael Guarnieri